Liver X Receptor-activating Ligands Modulate Renal and Intestinal Sodium-phosphate Transporters

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2011 Jun 17

PMID 21677638

Citations 13

Authors

Yupanqui A Caldas

Hector Giral

Michael A Cortazar

Eileen Sutherland

Kayo Okamura

Judith Blaine

Victor Sorribas

Hermann Koepsell

Moshe Levi

Affiliations

Soon will be listed here.

Abstract

Cholesterol is pumped out of the cells in different tissues, including the vasculature, intestine, liver, and kidney, by the ATP-binding cassette transporters. Ligands that activate the liver X receptor (LXR) modulate this efflux. Here we determined the effects of LXR agonists on the regulation of phosphate transporters. Phosphate homeostasis is regulated by the coordinated action of the intestinal and renal sodium-phosphate (NaPi) transporters, and the loss of this regulation causes hyperphosphatemia. Mice treated with DMHCA or TO901317, two LXR agonists that prevent atherosclerosis in ApoE or LDLR knockout mice, significantly decreased the activity of intestinal and kidney proximal tubular brush border membrane sodium gradient-dependent phosphate uptake, decreased serum phosphate, and increased urine phosphate excretion. The effects of DMHCA were due to a significant decrease in the abundance of the intestinal and renal NaPi transport proteins. The same effect was also found in opossum kidney cells in culture after treatment with either agonist. There was increased nuclear expression of the endogenous LXR receptor, a reduction in NaPi4 protein abundance (the main type II NaPi transporter in the opossum cells), and a reduction in NaPi co-transport activity. Thus, LXR agonists modulate intestinal and renal NaPi transporters and, in turn, serum phosphate levels.

Citing Articles

The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota.

Wang M, Huang Z, Zhu Y, Li X, Sun H, Fan Q Kidney Int Rep. 2025; 10(2):522-534.

PMID: 39990894 PMC: 11843129. DOI: 10.1016/j.ekir.2024.11.022.

Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease.

Mitrofanova A, Merscher S, Fornoni A Nat Rev Nephrol. 2023; 19(10):629-645.

PMID: 37500941 DOI: 10.1038/s41581-023-00741-w.

Enhanced phosphate absorption in intestinal epithelial cell-specific NHE3 knockout mice.

Xue J, Thomas L, Murali S, Levi M, Fenton R, Dominguez Rieg J Acta Physiol (Oxf). 2022; 234(2):e13756.

PMID: 34978760 PMC: 9286053. DOI: 10.1111/apha.13756.

Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease.

Wright M, Varona Santos J, Kemmer C, Maugeais C, Carralot J, Roever S Nat Commun. 2021; 12(1):4662.

PMID: 34341345 PMC: 8329197. DOI: 10.1038/s41467-021-24890-3.

Nuclear receptors in the kidney during health and disease.

Libby A, Jones B, Lopez-Santiago I, Rowland E, Levi M Mol Aspects Med. 2020; 78:100935.

PMID: 33272705 PMC: 7987687. DOI: 10.1016/j.mam.2020.100935.

References

Kratzer A, Buchebner M, Pfeifer T, Becker T, Uray G, Miyazaki M . Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 2008; 50(2):312-26. PMC: 2636920. DOI: 10.1194/jlr.M800376-JLR200. View

Kiela P, Ghishan F . Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest. 2008; 89(1):7-14. PMC: 4292907. DOI: 10.1038/labinvest.2008.114. View

Foley R . Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009; 4(6):1136-9. DOI: 10.2215/CJN.01660309. View

Hong C, Tontonoz P . Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev. 2008; 18(5):461-7. PMC: 2641014. DOI: 10.1016/j.gde.2008.07.016. View

Chiu Y, Adler S, Budoff M, Takasu J, Ashai J, Mehrotra R . Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010; 77(12):1107-14. DOI: 10.1038/ki.2010.70. View

Breusegem S, Takahashi H, Giral-Arnal H, Wang X, Jiang T, Verlander J . Differential regulation of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, and PiT-2 in dietary potassium deficiency. Am J Physiol Renal Physiol. 2009; 297(2):F350-61. PMC: 2724260. DOI: 10.1152/ajprenal.90765.2008. View

Breusegem S, Halaihel N, Inoue M, Zajicek H, Lederer E, Barry N . Acute and chronic changes in cholesterol modulate Na-Pi cotransport activity in OK cells. Am J Physiol Renal Physiol. 2005; 289(1):F154-65. DOI: 10.1152/ajprenal.00331.2004. View

Bensinger S, Bradley M, Joseph S, Zelcer N, Janssen E, Hausner M . LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008; 134(1):97-111. PMC: 2626438. DOI: 10.1016/j.cell.2008.04.052. View

Janowski B, Willy P, Devi T, Falck J, Mangelsdorf D . An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383(6602):728-31. DOI: 10.1038/383728a0. View

10.

Villa-Bellosta R, Bogaert Y, Levi M, Sorribas V . Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol. 2007; 27(5):1030-6. DOI: 10.1161/ATVBAHA.106.132266. View

11.

Joseph S, McKilligin E, Pei L, Watson M, Collins A, Laffitte B . Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002; 99(11):7604-9. PMC: 124297. DOI: 10.1073/pnas.112059299. View

12.

Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J . Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online). 2007; 61:736-59. View

13.

Lanaspa M, Giral H, Breusegem S, Halaihel N, Baile G, Catalan J . Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am J Physiol Renal Physiol. 2006; 292(1):F230-42. DOI: 10.1152/ajprenal.00075.2006. View

14.

Tontonoz P, Mangelsdorf D . Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003; 17(6):985-93. DOI: 10.1210/me.2003-0061. View

15.

Kaneko E, Matsuda M, Yamada Y, Tachibana Y, Shimomura I, Makishima M . Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem. 2003; 278(38):36091-8. DOI: 10.1074/jbc.M304153200. View

16.

Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N . Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009; 297(5):F1466-75. PMC: 2781338. DOI: 10.1152/ajprenal.00279.2009. View

17.

Hansen M, Connolly T . Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr Opin Investig Drugs. 2008; 9(3):247-55. View

18.

Villa-Bellosta R, Sorribas V . Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Arch. 2009; 459(3):499-508. DOI: 10.1007/s00424-009-0746-z. View

19.

Kalaany N, Mangelsdorf D . LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006; 68:159-91. DOI: 10.1146/annurev.physiol.68.033104.152158. View

20.

Zhang Y, Mangelsdorf D . LuXuRies of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. Mol Interv. 2004; 2(2):78-87. DOI: 10.1124/mi.2.2.78. View